• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

DrFirst Partners with Greenway to Bring Controlled Substance E-prescribing to Greenway Users Nationwide

by Jasmine Pennic 02/24/2014 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

DrFirst, a leading provider of healthcare IT solutions designed to improve clinical outcomes for patients, today announced a partnership to bring electronic prescribing of controlled substances (EPCS) to Greenway’s network of thousands of healthcare providers across primary care and more than 30 specialties.

U.S. providers are increasingly prescribing controlled substances electronically in order to improve safety, efficiency and security. Controlled substance e-prescribing, which is now legal in 47 states and available through nearly one-third of U.S. pharmacies, will become mandatory in the state of New York by March 27, 2015 due to the Internet System for Tracking Over-Prescribing/Prescription Monitoring Program (I-STOP) legislation.

DrFirst’s EPCS Gold℠ 2.0 software will be integrated into Greenway’s Intergy, PrimeSUITE and SuccessEHS systems.

“We chose DrFirst for controlled substance e-prescribing based on its industry-leading expertise, its total-solution support covering the identity proofing process, token management and end-user onboarding, as well as the flexibility of its technology which will enable us to integrate EPCS Gold into all three of our EHR software platforms,” said Mark Janiszewski, Greenway senior vice president of product management.

“DrFirst’s architecture allows us to rapidly integrate and bring controlled substance e-prescribing to our users with a consistent and simple user interface,” he continued. “Since EPCS Gold is also fully compliant with DEA rules and NIST identity-proofing standards, DrFirst’s solution brings our users tremendous value.”

“With the increased scrutiny by the healthcare industry on prescription drug abuse, EPCS Gold provides Greenway customers with a powerful tool to prevent doctor shopping and prescription drug fraud,” said G. Cameron Deemer, president of DrFirst. “As a progressive healthcare technology company, Greenway recognizes and embraces the importance of bringing controlled substance e-prescribing to its users, and delivering the advantage of a single e-prescribing workflow for both legend and controlled drugs.”

To download DrFirst’s 2014 report on electronic prescribing of controlled substances, “The Evolving Landscape for Electronic Prescribing of Controlled Substances (EPCS) — An Industry Briefing for 2014,” visit http://go.drfirst.com/EPCSreport2014.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |